<DOC>
	<DOCNO>NCT01473732</DOCNO>
	<brief_summary>The purpose study find well current drug regimen ( include low Prograf dose Myfortic , usually recommend prevent deterioration kidney function ) work safe compare combination Zortress Myfortic patient chronic kidney injury associate Prograf Neoral use .</brief_summary>
	<brief_title>Mechanisms Treatment Chronic Allograft Injury ( CAI ) Due Calcineurin Inhibitor ( CNI ) Toxicity</brief_title>
	<detailed_description>Specific Aim 1 : To investigate allograft peripheral blood cell gene expression pattern patient CAI use Affymetrix microarrays . Hypothesis 1 : Gene expression pattern patient biopsy finding suggest calcineurin inhibitor ( CNI ) toxicity without significant tubulointerstitial infiltrates transplant glomerulopathy might demonstrate upregulation gene relate tissue injury , fibrosis , extracellular matrix deposition without upregulation gene relate alloimmune response , , T and/or B lymphocyte activation marker , surface receptor , co-stimulation molecule , adhesion molecule , cytokine , chemokines compare patient significant tubulointerstitial infiltrates and/or transplant glomerulopathy might show upregulation gene relate alloimmune response , , T and/or B lymphocyte activation marker , surface receptor , co-stimulation molecule , adhesion molecule , cytokine , chemokines . Specific Aim 2 : The effect everolimus ( Zortress ) / mycophenolate sodium ( EC-MPS , myfortic® ) treatment allograft peripheral gene expression pattern . Hypothesis 2 : Everolimus ( Zortress ) mycophenolate sodium ( EC-MPS , myfortic® ) treatment attenuate progression CAI due CNI toxicity downregulating expression gene relate fibrosis , , transform growth factor-β , thrombospondin 1 , platelet derive growth factor-C . Specific Aim 3 : To document clinical outcome everolimus ( Zortress ) mycophenolate sodium ( EC-MPS , myfortic® ) patient CAI due CNI toxicity Hypothesis 3 : Everolimus ( Zortress ) mycophenolate sodium ( EC-MPS , myfortic® ) attenuate progression CAI due CNI toxicity may improve creatinine clearance .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>All patient biopsy proven pure chronic allograft injury due CNI toxicity . 1 . 24 hour urine protein spot urine protein/creatinine ratio &gt; 500 mg/day 2. eGFR &lt; 30 ml/min MDRD 24 hour urine collection 3 . Patients DSAs Luminex ( mean fluorescence intensity value &gt; 1,000 ) 4 . Recipients multiple organ transplant ABOincompatible allograft 5 . Current PRA great 30 percent 6 . Graft loss randomization 7 . Pregnant woman 8 . Previous history acute rejection 9 . Previous history allergy intolerance Zortress Myfortic 10 . Platelet count less 100,000 11 . WBC less 3,000 12 . Hb le 9 g/dL Htc le 30 % 13 . Biopsy find Chronic antibody mediate rejection Acute rejection Positive C4d stain Interstitial infiltrate 25 % area Transplant glomerulopathy Recurrent de novo glomerular disease Polyoma nephropathy positive SV40 staining</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>CNI toxicity</keyword>
	<keyword>CAI</keyword>
</DOC>